Biogen Makes Lifecycle Gambit In Next-Gen MS Drug Deal With Alkermes

27 Nov 2017

ALKS 8700 could help Biogen extend its MS franchise beyond Tecfidera. The next-generation fumarate may have better GI tolerability and patent protection into 2033.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Alkermes PLC has signed the most obvious partner for its late-stage multiple sclerosis drug, Biogen Inc., in a deal that seems advantageous to both companies. The Phase III next-generation fumarate ALKS 8700 could offer potential tolerability advantages compared to Biogen's currently marketed Tecfidera (dimethyl fumarate) and importantly is patent protected until 2033.

Thus, the deal announced Nov. 27 appears to be a sensible lifecycle-extension gambit for Biogen if it can successfully differentiate...